Generated by AI
MDxHealth SA is a commercial-stage precision diagnostics company focused on molecular testing for urologic diseases. MDxHealth SA develops and commercializes diagnostic solutions that help physicians assess the presence, risk, and management of prostate cancer, bladder cancer, and urinary tract infections. Its portfolio includes tissue- and urine-based tests that use genomic, epigenetic, exosomal, and other molecular technologies to support more informed clinical decision-making. The company serves healthcare providers and patients across the United States, Europe, and other international markets, with laboratory and commercial operations supporting the delivery of its tests. MDxHealth SA plays a role in the broader diagnostics market by providing actionable molecular information designed to improve the precision of cancer and infection diagnosis and treatment planning.
WebsiteCAP Business Center
Herstal, 4040
Belgium
The latest articles about MDXH.
Summary of Oct 30's posts. Generated by AI.
Summary of Aug 14's posts. Generated by AI.
Summary of Oct 30's posts. Generated by AI.
Investors talking about MDXH also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.